Company / Financials
Hepion Pharmaceuticals, Inc. Financials
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2023
Net Income
-$48.9M
FY2023 · -15.9% YoY
Profit Margin
-
FY2023 · net income / revenue
ROE
-672.0%
FY2023 · return on equity
Total Assets
$18.1M
FY2023
Total Debt
-
FY2023
Equity
$7.3M
FY2023
ROA
-270.4%
FY2023 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -18.07 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$48.9M-15.9% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$48.4M-6.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$9.6M-7.1% YoYR&D Expense HistoryResearch and development spending$35.6M+7.1% YoYInterest Expense HistoryCost of borrowing and debt obligations$9.5K-6.9% YoYIncome Tax HistoryTotal income tax expense-$409.0K+85.8% YoYEPS (Basic) HistoryBasic earnings per share-$11.90-2431.9% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$11.90-2431.9% YoYShares Outstanding HistoryWeighted average diluted shares outstanding3.8M-95.0% YoY